Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus

Summary: Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting exp...

Full description

Bibliographic Details
Main Author: Jean-François Rossignol
Format: Article
Language:English
Published: Elsevier 2016-05-01
Series:Journal of Infection and Public Health
Online Access:http://www.sciencedirect.com/science/article/pii/S1876034116300181
id doaj-8d7bc7c7794541b0b08c44aef817d3d7
record_format Article
spelling doaj-8d7bc7c7794541b0b08c44aef817d3d72020-11-24T21:29:10ZengElsevierJournal of Infection and Public Health1876-03412016-05-0193227230Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirusJean-François Rossignol0Correspondence to: Romark Laboratories, L.C., 3000 Bayport Drive, Suite 200, Tampa, FL 33607, United States.; Romark Laboratories, L.C., Tampa, FL, United StatesSummary: Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals. Keywords: Nitazoxanide, Coronavirus, MERS-CoV, Treatmenthttp://www.sciencedirect.com/science/article/pii/S1876034116300181
collection DOAJ
language English
format Article
sources DOAJ
author Jean-François Rossignol
spellingShingle Jean-François Rossignol
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Journal of Infection and Public Health
author_facet Jean-François Rossignol
author_sort Jean-François Rossignol
title Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
title_short Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
title_full Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
title_fullStr Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
title_full_unstemmed Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
title_sort nitazoxanide, a new drug candidate for the treatment of middle east respiratory syndrome coronavirus
publisher Elsevier
series Journal of Infection and Public Health
issn 1876-0341
publishDate 2016-05-01
description Summary: Nitazoxanide is a broad-spectrum antiviral agent undergoing clinical development for treatment of influenza and other viral respiratory infections. Nitazoxanide exhibits in vitro activity against Middle East respiratory syndrome coronavirus (MERS-CoV) and other coronaviruses, inhibiting expression of the viral N protein. Nitazoxanide also suppresses production of pro-inflammatory cytokines in peripheral blood mononuclear cells and suppresses interleukin 6 production in mice. Having been used extensively in clinical trials and in post-marketing experience, nitazoxanide is an attractive drug candidate for treatment of Middle East respiratory syndrome. Future research should include in vitro mechanism studies, animal models of MERS-CoV infection, clinical trials, including dose-ranging trials, and evaluation of combination therapy with other potential MERS-CoV antivirals. Keywords: Nitazoxanide, Coronavirus, MERS-CoV, Treatment
url http://www.sciencedirect.com/science/article/pii/S1876034116300181
work_keys_str_mv AT jeanfrancoisrossignol nitazoxanideanewdrugcandidateforthetreatmentofmiddleeastrespiratorysyndromecoronavirus
_version_ 1725966952628748288

Similar Items